Haha my post yesterday was timely. Looks like a net positive year with no reason to go backwards, considering the locked in contracts.
▪ FY22 Total Revenue of $14.3m; 215% growth on FY21 ($4.5m), 3.8% increase on Prospectus forecast
▪ Pro forma EBITDA of $1.45m; +$2.2m growth on FY21 (-$0.7m), 57% increase on Prospectus forecast
▪ Average PhotonAssayTM unit Utilisation of 66% across deployed assets; an increase on 41.6% in FY21
▪ Operating cash flow positive, with cash balance of $92m as at 30 June 2022
▪ Return on Invested Capital (ROIC) increasing from 34% to 47% with the addition of 15 new agreements since IPO and correspondingly higher unit TCV
Also worth noting there's $90M+ cash on hand end-June! That's a huge amount of capital for growth, considering they're making money already.
GLTAH
Haha my post yesterday was timely. Looks like a net positive...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add C79 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.55 |
Change
-0.050(0.89%) |
Mkt cap ! $638.1M | |||
| Open | High | Low | Value | Volume |
| $5.62 | $5.75 | $5.53 | $792.0K | 140.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 250 | $5.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.66 | 417 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| C79 (ASX) Chart |